A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Inclusion Criteria: * End-stage renal disease. * No known contraindications for therapy with IVIG 10%/Actemra®. * Age 18-65 years at the time of screening. * CPRA \> 50% demonstrated on 3 consecutive samples, UNOS wait time sufficient to allow DD offers, history of sensitizing events, positive crossmatch with the intended donor. LDs with DSA and Crossmatch positivity. * Subject/Parent/Guardian must be able to understand and provide informed consent. Exclusion Criteria: * Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization. * Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening. * Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti¬CD3, anti-CD19 and anti-CD20 within 6 months of baseline. * Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline * Immunization with a live/attenuated vaccine within 2 months prior to baseline. * Previous treatment with TCZ (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case-by-case basis). * Any previous treatment with alkylating agents such as chlorambucil, (within 1 year) or with total lymphoid irradiation. Exclusions for General Safety: * History of seve…